A health startup has raised £2 million for at-home testing using biomarkers.

London-based Sanome raised its first round of funding from a number of leading UK and European HealthTech specialist investors.

The round was led by Heal Capital, with participation from Crista Galli Ventures, Selvedge Ventures, o2h Ventures, Meltwind and a number of high-profile angels including David Cleevely and Pam Garside.

Sanome has developed a diagnostics innovation engine that combines biomarkers to develop medical grade, at-home diagnostic products more efficiently and effectively. Most digital health, wearables and consumer biotech tools have limited medical use because it’s hard to validate them clinically. 

Sanome’s novel approach leverages these existing technologies to develop at-home tests that are clinically validated to improve patient outcomes and reduce healthcare costs – ultimately laying the foundation for the early detection and prevention of diseases of high unmet need.

Sanome was founded by experienced entrepreneurs Benedikt von Thüngen (CEO) and Dr Marc van der Schee (Chief Medical Officer). They combine a unique set of experiences including software, clinical, healthcare, AI/ ML and biomarker development, as well as having built and scaled multiple successful companies before, including Owlstone Medical and Speechmatics.

The investment will be used to expand the team across London, Amsterdam, and Cambridge; deliver on key strategic and commercial partnerships to develop and validate the first set of IVD candidates.

“Healthcare touches each and every one of us and the recent pandemic has highlighted that at a global level,” said CEO Von Thüngen. 

“It showed the need to bring healthcare closer to people’s homes and that we need to leverage many of the recent innovations in digital health and consumer BioTech to capture as many data points about human health as possible. 

“This will transform our understanding of the human body and our approach to disease detection and management.”

Eckhardt Weber, partner at Heal Capital, commented: “Sanome will change the way patients, providers and payers interact with healthcare. 

“By pioneering a new model for IVD innovation, they can create medical-grade diagnostics that truly focus on solving our healthcare system’s most pressing problems. 

“We could not be happier to be supporting Sanome’s exceptional founding team on the journey to make healthcare inclusive, preventative and proactive.”